Pelacarsen reduces the need for lipoprotein apheresis (LA) in patients with elevated Lp(a) and cardiovascular disease (CVD), according to results of the Phase 3 Lp(a)FRONTIERS APHERESIS trial carried out in Germany.
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
